Current approaches to the management of diabetic retinopathy and diabetic macular oedema

Drugs

Volumn 70, Issue 16, 2010, Pages 2171-2200

  Boscia, Francesco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Aspirin; Atorvastatin; Bevacizumab; Candesartan cilexetil; Corticosteroids; Diabetic macular oedema; Diabetic retinopathy; Enalapril; Fenofibrate; Infliximab; Laser therapy; Lisinopril; Losartan; Mecamylamine; Pegaptanib; Perindopril; PF 4523655; Ranibizumab; Ruboxistaurin; Triamcinolone

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEVACIZUMAB; BEVASIRANIB; CANDESARTAN HEXETIL; CORTICOSTEROID; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; HEMOGLOBIN A1C; INSULIN; LISINOPRIL; LOSARTAN; MICROPLASMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAPTANIB; PLACEBO; RANIBIZUMAB; RUBOXISTAURIN; SIMVASTATIN; SULINDAC; TRIAMCINOLONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; VITREOSOLVE;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; APOPTOSIS; BLOOD PRESSURE REGULATION; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CATARACT; CILIARY DISK; CLINICAL FEATURE; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; LASER COAGULATION; MICROANEURYSM; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONPROLIFERATIVE VITREORETINAL DISEASE; OFF LABEL DRUG USE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD FLOW; RETINA DETACHMENT; RETINA MACULA HOLE; REVIEW; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 77958566857     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11538130-000000000-00000     Document Type: Review

References (317)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data onvisual impairment in the year 2002. Bull World Health Organ 2004; 82 (11): 844-51
2. Mohamed Q, Wong TY. Emerging drugs for diabetic ret-inopathy. Expert Opin Emerg Drugs 2008; 13 (4): 675-94
3. Masharani U, Rushakoff RJ. Update on systemic manage-ment of diabetes. Int Ophthalmol Clin 2009; 49 (2): 13-33
4. Nathan DM, Zinman B, Cleary PA, et al., on behalf of theDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169 (14): 1307-16
5. Wong TY, Mwamburi M, Klein R, et al. Rates of pro-gression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009; 32 (12): 2307-13
6. Klein R, Lee KE, Knudtson MD, et al. Changes in visualimpairment prevalence by period of diagnosis of diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinop-athy. Ophthalmology 2009; 116 (10): 1937-42
7. Romero-Aroca P, Fernandez-Balart J, Baget-Bernaldiz M,et al. Changes in the diabetic retinopathy epidemiology after 14 years in a population of type 1 and 2 diabetic patients after the new diabetes mellitus diagnosis criteria and a more strict control of the patients. J Diabetes Complications 2009; 23 (4): 229-38
8. Heintz E, Wirehn AB, Peebo BB, et al. Prevalence andhealthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010 Oct; 53 (10): 2147-54
9. Knudsen LL, Lervang HH, Lundbye-Christensen S, et al.The North Jutland County Diabetic Retinopathy Study: population characteristics. Br J Ophthalmol 2006; 90 (11): 1404-9
10. Hove MN, Kristensen JK, Lauritzen T, et al. The prev-alence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol Scand 2004; 82 (4): 443-8
11. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of dia-betic retinopathy in the United States, 2005-2008. JAMA 2010; 304 (6): 649-56
12. Klein R, Knudtson MD, Lee KE, et al. The WisconsinEpidemiologic Study of Diabetic Retinopathy XXII: the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115 (11): 1859-68
13. Saaddine JB, Honeycutt AA, Narayan KM, et al. Projec-tion of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 2008; 126 (12): 1740-7
14. Kempen JH, O'Colmain BJ, Leske MC, et al. The prev-alence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122 (4): 552-63
15. Singh A, Stewart JM. Pathophysiology of diabetic macularedema. Int Ophthalmol Clin 2009; 49 (2): 1-11
16. Gardner TW, Antonetti DA. Novel potential mechanismsfor diabetic macular edema: leveraging new investiga-tional approaches. Curr Diab Rep 2008; 8 (4): 263-9
17. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic macularedema: pathogenesis and treatment. Surv Ophthalmol 2009; 54 (1): 1-32
18. Chen E, Looman M, Laouri M, et al. Burden of illness ofdiabetic macular edema: literature review. Curr Med Res Opin 2010; 26 (7): 1587-97
19. Knudsen LL, Lervang HH, Lundbye-Christensen S, et al.The North Jutland County Diabetic Retinopathy Study (NCDRS) 2: non-ophthalmic parameters and clinically significant macular oedema. Br J Ophthalmol 2007; 91 (12): 1593-5
20. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epide-miologic Study of Diabetic Retinopathy. XV: the long-term incidence of macular edema. Ophthalmology 1995; 102 (1): 7-16
21. Klein R, Knudtson MD, Lee KE, et al. The WisconsinEpidemiologic Study of Diabetic Retinopathy. XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116 (3): 497-503
22. Shea AM, Curtis LH, Hammill BG, et al. Resource use andcosts associated with diabetic macular edema in elderly persons. Arch Ophthalmol 2008; 126 (12): 1748-54
23. Fong DS, Aiello LP, Ferris 3rd FL, et al. Diabetic retinop-athy. Diabetes Care 2004; 27 (10): 2540-53
24. Baskin DE. Optical coherence tomography in diabeticmacular edema. Curr Opin Ophthalmol 2010; 21 (3): 172-7
25. Chan A, Duker JS. A standardized method for reportingchanges in macular thickening using optical coherence tomography. Arch Ophthalmol 2005; 123 (7): 939-43
26. Kim BY, Smith SD, Kaiser PK. Optical coherence tomo-graphic patterns of diabetic macular edema. Am J Oph-thalmol 2006; 142 (3): 406-12
27. Ophir A, Martinez MR, Mosqueda P, et al. Vitreous trac-tion and epiretinal membranes in diabetic macular oedema using spectral-domain optical coherence tomography. Eye (Lond). Epub 2010 Jun 4
28. Otani T, Kishi S, Maruyama Y. Patterns of diabetic mac-ular edema with optical coherence tomography. Am J Ophthalmol 1999; 127 (6): 688-93
29. Buabbud JC, Al-latayfeh MM, Sun JK. Optical coherencetomography imaging for diabetic retinopathy and mac-ular edema. Curr Diab Rep 2010; 10 (4): 264-9
30. Forte R, Cennamo GL, Finelli ML, et al. Comparison oftime domain Stratus OCT and spectral domain SLO/OCTfor assessment of macular thickness and volume. Eye (Lond) 2009; 23 (11): 2071-8
31. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009; 50 (7): 3432-7
32. Pournaras JA, Erginay A, Lazrak Z, et al. Spectral domainoptical coherence tomography in diabetic macular edema. Ophthalmic Surg Lasers Imaging 2009; 40 (6): 548-53
33. Geitzenauer W, Kiss CG, Durbin MK, et al. Compar-ing retinal thickness measurements from cirrus spectral domain-and stratus time domain-optical coherence tomography. Retina 2010; 30 (4): 596-606
34. Aiello LP, Gardner TW, King GL, et al. Diabetic retinop-athy. Diabetes Care 1998; 21 (1): 143-56
35. Kroll P, Rodrigues EB, Hoerle S. Pathogenesis and classi-fication of proliferative diabetic vitreoretinopathy. Oph-thalmologica 2007; 221 (2): 78-94
36. ETDRS Research Group. Photocoagulation for diabeticmacular edema: Early Treatment Diabetic Retinopathy Study report no. 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103 (12): 1796-806
37. Ahmadi MA, Lim JI. Update on laser treatment of diabeticmacular edema. Int Ophthalmol Clin 2009; 49 (2): 87-94
38. International Council of Ophthalmology. Visual stan-dards: aspects and ranges of vision loss with emphasis on population surveys. Report prepared for the International Council of Ophthalmology at the 29th International Congress of Ophthalmology, Sydney, Australia, April 2002 [online]. Available from URL: http://www.icoph. org/pdf/visualstandardsreport.pdf [Accessed 2010 May 5].
39. Starita C, Patel M, Katz B, et al. Vascular endothelialgrowth factor and the potential therapeutic use of pe-gaptanib (Macugen) in diabetic retinopathy. Dev Oph-thalmol 2007; 39: 122-48
40. Browning DJ, Altaweel MM, Bressler NM, et al. Diabeticmacular edema: what is focal and what is diffuse? Am J Ophthalmol 2008; 146 (5): 649-55
41. Gardner TW, Antonetti DA, Barber AJ, et al. Diabeticretinopathy: more than meets the eye. Surv Ophthalmol 2002; 47 Suppl. 2: S253-62
42. Mortlock KE, Chiti Z, Drasdo N, et al. Silent substitutionS-cone electroretinogram in subjects with diabetes melli-tus. Ophthalmic Physiol Opt 2005; 25 (5): 392-9
43. Georgakopoulos CD, Eliopoulou MI, Exarchou AM, et al.Decreased contrast sensitivity in children and adolescents with type 1 diabetes mellitus. J Pediatr Ophthalmol Strabismus. Epub 2010 Apr 30: 1-6
44. Parisi V, Uccioli L. Visual electrophysiological responses inpersons with type 1 diabetes. Diabetes Metab Res Rev 2001; 17 (1): 12-8
45. Bronson-Castain KW, Bearse Jr MA, Neuville J, et al.Adolescents with type 2 diabetes: early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina 2009; 29 (5): 618-26
46. Lakhani E, Wright T, Abdolell M, et al. Insufficient long-term glycemic control is associated with multifocal ERG defects in adolescents with type 1 diabetes. Invest Oph-thalmol Vis Sci. Epub 2010 May 19
47. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in theretina during experimental and human diabetes: early onset and effect of insulin. J Clin Invest 1998; 102 (4): 783-91
48. van Dijk HW, Kok PH, Garvin M, et al. Selective loss ofinner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50 (7): 3404-9
49. Cabrera DeBuc D, Somfai GM. Early detection of retinalthickness changes in diabetes using optical coherence tomography. Med Sci Monit 2010; 16 (3): MT15-21
50. van Dijk HW, Verbraak FD, Kok PH, et al. Decreasedretinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci 2010; 51 (7): 3660-5
51. Verma A, Rani PK, Raman R, et al. Is neuronal dysfunc-tion an early sign of diabetic retinopathy? Microperimetry and spectral domain optical coherence tomography (SD-OCT) study in individuals with diabetes, but no diabetic retinopathy. Eye (Lond) 2009; 23 (9): 1824-30
52. Joussen AM, Murata T, Tsujikawa A, et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158 (1): 147-52
53. Bursell SE, Clermont AC, Kinsley BT, et al. Retinal bloodflow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37 (5): 886-97
54. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesionsof diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond) 2009; 23 (7): 1496-508
55. Ejaz S, Chekarova I, Ejaz A, et al. Importance of pericytesand mechanisms of pericyte loss during diabetes retinop-athy. Diabetes Obes Metab 2008; 10 (1): 53-63
56. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascularendothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19 (6): 442-55
57. Diabetes Control and Complications Trial ResearchGroup. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86
58. Diabetes Control and Complications Trial ResearchGroup. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995; 102 (4): 647-61
59. Kalesnykiene V, Sorri I, Voutilainen R, et al. The effect ofglycaemic control on the quantitative characteristics of retinopathy lesions in patients with type 2 diabetes melli-tus: 10-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2009; 247 (3): 335-41
60. Lorenzi M. The polyol pathway as a mechanism for dia-betic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res 2007; 2007: 61038
61. Goh SY, Cooper ME. Clinical review: the role of advancedglycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93 (4): 1143-52
62. Kaji Y, Usui T, Ishida S, et al. Inhibition of diabeticleukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci 2007; 48 (2): 858-65
63. Pachydaki SI, Tari SR, Lee SE, et al. Upregulation ofRAGE and its ligands in proliferative retinal disease. Exp Eye Res 2006; 82 (5): 807-15
64. Zheng L, Du Y, Miller C, et al. Critical role of induciblenitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetolo-gia 2007; 50 (9): 1987-96
65. Clarke M, Dodson PM. PKC inhibition and diabetic mi-crovascular complications. Best Pract Res Clin En-docrinol Metab 2007; 21 (4): 573-86
66. Adamis AP, Berman AJ. Immunological mechanisms inthe pathogenesis of diabetic retinopathy. Semin Im-munopathol 2008; 30 (2): 65-84
67. Wirostko B, Wong TY, Simo R. Vascular endothelialgrowth factor and diabetic complications. Prog Retin Eye Res 2008; 27 (6): 608-21
68. Kern TS. Contributions of inflammatory processes to thedevelopment of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007: 95103
69. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidalanti-inflammatory drugs prevent early diabetic retinop-athy via TNF-alpha suppression. FASEB J 2002; 16 (3): 438-40
70. Gao BB, Clermont A, Rook S, et al. Extracellular carbonicanhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13 (2): 181-8
71. Chen P, Scicli GM, Guo M, et al. Role of angiotensin II inretinal leukostasis in the diabetic rat. Exp Eye Res 2006; 83 (5): 1041-51
72. Nagai N, Izumi-Nagai K, Oike Y, et al. Suppression ofdiabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 2007; 48 (9): 4342-50
73. Kim JH, Kim JH, Yu YS, et al. Blockade of angiotensin IIattenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab 2009; 29 (3): 621-8
74. Diabetes Control and Complications Trial Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342 (6): 381-9
75. Diabetes Control and Complications Trial/Epidemiologyof Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287 (19): 2563-9
76. White NH, Sun W, Cleary PA, et al. Prolonged effect ofintensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Oph-thalmol 2008; 126 (12): 1707-15
77. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53
78. Mohamed Q, Gillies MC, Wong TY. Management of dia-betic retinopathy: a systematic review. JAMA 2007; 298 (8): 902-16
79. UK Prospective Diabetes Study Group. Tight blood pres-sure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160): 703-13
80. Schrier RW, Estacio RO, Esler A, et al. Effects of ag-gressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61 (3): 1086-97
81. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect oflisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group: EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351 (9095): 28-31
82. Chaturvedi N, Porta M, Klein R, et al. Effect of can-desartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372 (9647): 1394-402
83. Sjolie AK, Klein R, Porta M, et al. Effect of candesartan onprogression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372 (9647): 1385-93
84. Keech AC, Mitchell P, Summanen PA, et al. Effect of fe-nofibrate on the need for laser treatment for diabetic ret-inopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370 (9600): 1687-97
85. White NH, Cleary PA, Dahms W, et al. Beneficial effects ofintensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001; 139 (6): 804-12
86. White NH, Sun W, Cleary PA, et al. Effect of prior in-tensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010; 59 (5): 1244-53
87. Chew EY, Ambrosius WT, Davis MD, et al. Effects ofmedical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363 (3): 233-44
88. Gerstein HC, Miller ME, Byington RP, et al. Effects ofintensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24): 2545-59
89. Diabetes Control and Complications Trial ResearchGroup. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Oph-thalmol 1998; 116 (7): 874-86
90. Egger M, Davey Smith G, Stettler C, et al. Risk of adverseeffects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med 1997; 14 (11): 919-28
91. Beulens JW, Patel A, Vingerling JR, et al., on behalf of theAdRem project team and ADVANCE management committee. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 2009; 52 (10): 2027-36
92. Patel A, MacMahon S, Chalmers J, et al. Intensive bloodglucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24): 2560-72
93. Klein R, Klein BE, Moss SE, et al. Is blood pressure apredictor of the incidence or progression of diabetic ret-inopathy? Arch Intern Med 1989; 149 (11): 2427-32
94. van Leiden HA, Dekker JM, Moll AC, et al. Blood pres-sure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care 2002; 25 (8): 1320-5
95. Chatziralli IP, Sergentanis TN, Keryttopoulos P, et al. Riskfactors associated with diabetic retinopathy in patients with diabetes mellitus type 2. BMC Res Notes 2010; 3: 153
96. Estacio RO, Jeffers BW, Gifford N, et al. Effect of bloodpressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl. 2: B54-64
97. Mauer M, Zinman B, Gardiner R, et al. Renal and retinaleffects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361 (1): 40-51
98. Ruggenenti P, Iliev I, Filipponi M, et al. Effect of trando-lapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the BENEDICT trial. J Ophthalmol. Epub 2010 Jun 10
99. Fletcher EL, Phipps JA, Ward MM, et al. The renin-angiotensin system in retinal health and disease: its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010; 29 (4): 284-311
100. Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008; 57 (8): 2191-8
101. Schupp M, Janke J, Clasen R, et al. Angiotensin type q1receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109 (17): 2054-7
102. Dodson P. The effect of statins on diabetic retinopathy.American Diabetes Association 66th Scientific Sessions, Washington, DC, June 9-13, 2006. Webcast [online]. Available from URL: https://www.diabetesconnect.org/Adv-SearchResult. aspx?typ=10&sr=adv&cgr=9&tit=&spk=&ses=&kwd= atorvastatin; [Accessed 2009 Nov 18]
103. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009; 205 (1): 1-8
104. Kim J, Ahn JH, Kim JH, et al. Fenofibrate regulates retinalendothelial cell survival through the AMPK signal trans-duction pathway. Exp Eye Res 2007; 84 (5): 886-93
105. Biscetti F, Gaetani E, Flex A, et al. Selective activation ofperoxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 2008; 57 (5): 1394-404
106. Biscetti F, Straface G, Pitocco D, et al. Peroxisomeproliferator- activated receptors and angiogenesis. Nutr Metab Cardiovasc Dis 2009; 19 (11): 751-9
107. Klein BE. Reduction in risk of progression of diabetic ret-inopathy. N Engl J Med 2010; 363 (3): 287-8
108. Lang GE. Laser treatment of diabetic retinopathy. DevOphthalmol 2007; 39: 48-68
109. Diabetic Retinopathy Study Research Group. Indicationsfor photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. Int Ophthal-mol Clin 1987; 27 (4): 239-53
110. Neubauer AS, Ulbig MW. Laser treatment in diabetic ret-inopathy. Ophthalmologica 2007; 221 (2): 95-102
111. Fong DS, Girach A, Boney A. Visual side effects of suc-cessful scatter laser photocoagulation surgery for pro-liferative diabetic retinopathy: a literature review. Retina 2007; 27 (7): 816-24
112. Thompson MJ, Ip MS. Diabetic macular edema: a reviewof past, present, and future therapies. Int Ophthalmol Clin 2004; 44 (4): 51-67
113. Diabetic Retinopathy Study Research Group. Preliminaryreport on effects of photocoagulation therapy: the Diabetic Retinopathy Study Research Group. Am J Oph-thalmol 1976; 81 (4): 383-96
114. Early Treatment Diabetic Retinopathy Study ResearchGroup. Early photocoagulation for diabetic retinopathy: ETDRS report no. 9. Ophthalmology 1991; 98 (5 Suppl.): 766-85
115. Maeshima K, Utsugi-Sutoh N, Otani T, et al. Progressiveenlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 2004; 24 (4): 507-11
116. Schatz H, Madeira D, McDonald HR, et al. Progressiveenlargement of laser scars following grid laser photo-coagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991; 109 (11): 1549-51
117. Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis indiabetic macular edema: ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997; 115 (7): 873-7
118. Luttrull JK, Musch DC, Mainster MA. Subthreshold diodemicropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthal-mol 2005; 89 (1): 74-80
119. Moorman CM, Hamilton AM. Clinical applications of theMicroPulse diode laser. Eye 1999; 13 (Pt 2): 145-50
120. Sivaprasad S, Sandhu R, Tandon A, et al. Subthresholdmicropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clin Experiment Ophthalmol 2007; 35 (7): 640-4
121. Luttrull JK, Musch DC, Spink CA. Subthreshold diodemicropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye (Lond) 2008; 22 (5): 607-12
122. Fong DS, Strauber SF, Aiello LP, et al. Comparison of themodified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007; 125 (4): 469-80
123. Figueira J, Khan J, Nunes S, et al. Prospective randomisedcontrolled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009; 93 (10): 1341-4
124. Vujosevic S, Bottega E, Casciano M, et al. Microperimetryand fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagula-tion. Retina 2010; 30 (6): 908-16
125. Muqit MM, Wakely L, Stanga PE, et al. Effects of con-ventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy. Eye (Lond) 2010; 24 (7): 1136-42
126. Nagpal M, Marlecha S, Nagpal K. Comparison of laserphotocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina 2010; 30 (3): 452-8
127. Muqit MM, Marcellino GR, Henson DB, et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: the Manchester Pascal Study. Arch Ophthalmol 2010; 128 (5): 525-33
128. Christoforidis JB, D'Amico DJ. Surgical and other treat-ments of diabetic macular edema: an update. Int Oph-thalmol Clin 2004; 44 (1): 139-60
129. Ho T, Smiddy WE, Flynn Jr HW. Vitrectomy in the man-agement of diabetic eye disease. Surv Ophthalmol 1992; 37 (3): 190-202
130. Newman DK. Surgical management of the late complica-tions of proliferative diabetic retinopathy. Eye (Lond) 2010; 24 (3): 441-9
131. Diabetic Retinopathy Vitrectomy Study Group. Earlyvitrectomy for severe vitreous hemorrhage in diabetic ret-inopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990; 108 (7): 958-64
132. Chang PY, Yang CM, Yang CH, et al. Pars plana vit-rectomy for diabetic fibrovascular proliferation with and without internal limiting membrane peeling. Eye (Lond) 2009; 23 (4): 960-5
133. Helbig H. Surgery for diabetic retinopathy. Ophthalmolo-gica 2007; 221 (2): 103-11
134. Laidlaw DA. Vitrectomy for diabetic macular oedema. Eye2008; 22 (10): 1337-41
135. Kumagai K, Furukawa M, Ogino N, et al. Long-term fol-low-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009; 29 (4): 464-72
136. Goldenberg DT, Hassan TS. Small gauge, sutureless sur-gery techniques for diabetic vitrectomy. Int Ophthalmol Clin 2009; 49 (2): 141-51
137. Mason III JO, Colagross CT, Vail R. Diabetic vitrectomy:risks, prognosis, future trends. Curr Opin Ophthalmol 2006; 17 (3): 281-5
138. Yang SJ, Yoon SY, Kim JG, et al. Transconjunctival su-tureless vitrectomy for the treatment of vitreoretinal complications in patients with diabetes mellitus. Ophthalmic Surg Lasers Imaging 2009; 40 (5): 461-6
139. Park DH, Shin JP, Kim SY. Comparison of clinical out-comes between 23-gauge and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy. Retina. Epub 2010 Jul 24
140. Park KH, Woo SJ, Hwang JM, et al. Short-term outcomeof bimanual 23-gauge transconjunctival sutureless vit-rectomy for patients with complicated vitreoretinopathies. Ophthalmic Surg Lasers Imaging 2010; 41 (2): 207-14
141. Cheema RA, Mushtaq J, Cheema MA. Role of residualvitreous cortex removal in prevention of postoperative vitreous hemorrhage in diabetic vitrectomy. Int Ophthalmol 2010; 30 (2): 137-42
142. Oshima Y, Shima C, Wakabayashi T, et al. Microincisionvitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116 (5): 927-38
143. Modarres M, Nazari H, Falavarjani KG, et al. Intravitrealinjection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol 2009; 19 (5): 848-52
144. da R Lucena D, Ribeiro JA, Costa RA, et al. Intraoperativebleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol 2009; 93 (5): 688-91
145. Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreat-ment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29 (6): 768-74
146. Hattori T, Shimada H, Nakashizuka H, et al. Dose ofintravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina 2010; 30 (5): 761-4
147. Hornan D, Edmeades N, Krishnan R, et al. Use of pe-gaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy. Eye (Lond). Epub 2010 Mar 12
148. Ahmadieh H, Shoeibi N, Entezari M, et al. Intravitrealbevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients. Ophthalmology 2009; 116 (10):1943-8
149. di Lauro R, De Ruggiero P, di Lauro R, et al. Intravitrealbevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248 (6): 785-91
150. Hernandez-Da Mota SE, Nunez-Solorio SM. Experiencewith intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol. Epub 2010 Apr 23; 20 (6): 7
151. Park DH, Shin JP, Kim SY. Intravitreal injection of bev-acizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol 2010; 248 (5): 641-50
152. Lopez-Lopez F, Rodriguez-Blanco M, Gomez-Ulla F,et al. Enzymatic vitreolysis. Curr Diabetes Rev 2009; 5 (1): 57-62
153. Kuppermann BD, Thomas EL, de Smet MD, et al. Pooledefficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005; 140 (4): 573-84
154. A safety and efficacy study of Vitreosolve® for non-pro-liferative diabetic retinopathy subjects [ClinicalTrials.gov identifier NCT00908778]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
155. A multicenter study to compare multiple doses of in-travitreal microplasmin versus sham injection for treatment of patients with DME [ClinicalTrials.gov identifier NCT00412451]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Aug 17].
156. A study of the safety and efficacy of microplasmin to in-duce a posterior vitreous detachment (MIVI III) [Clin-icalTrials.gov identifier NCT00412958]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
157. Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology 2010; 117 (4): 791-7
158. Diaz-Llopis M, Udaondo P, Arevalo F, et al. Intravitrealplasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther 2009; 25 (4): 379-84
159. Powell ED, Field RA. Diabetic retinopathy and rheuma-toid arthritis. Lancet 1964; 41: 17-8
160. ETDRS Research Group. Effects of aspirin treatment ondiabetic retinopathy: ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98 (5 Suppl.): 757-65
161. DAMAD Study Group. Effect of aspirin alone and aspirinplus dipyridamole in early diabetic retinopathy: a multi-center randomized controlled clinical trial. Diabetes 1989; 38 (4): 491-8
162. Bergerhoff K, Clar C, Richter B. Aspirin in diabetic ret-inopathy: a systematic review. Endocrinol Metab Clin North Am 2002; 31 (3): 779-93
163. Hattori Y, Hashizume K, Nakajima K, et al. The effect oflong-term treatment with sulindac on the progression of diabetic retinopathy. Curr Med Res Opin 2007; 23 (8): 1913-7
164. Effect of topical nepafenac in macular thickening related topan-retinal photocoagulation [ClinicalTrials.gov identifier NCT00801905]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Aug 17].
165. Randomized, double blind trial of bromfenac BID (0.09%)as an adjunct to argon laser therapy in the treatment of diabetic macular edema [ClinicalTrials.gov identifier NCT00758628]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://www.cli nicaltrials.gov [Accessed 2010 Aug 17]
166. A clinical safety and efficacy comparison of NEVANAC0.1% to vehicle after cataract surgery in diabetic retinopathy patients [ClinicalTrials.gov identifier NCT00782717]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
167. Cunningham MA, Edelman JL, Kaushal S. Intravitrealsteroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008; 53 (2): 139-49
168. Grover D, Li TJ, Chong CC. Intravitreal steroids for mac-ular edema in diabetes. Cochrane Database Syst Rev 2008; (1): CD005656
169. Kuo CH, Gillies MC. Role of steroids in the treatment ofdiabetic macular edema. Int Ophthalmol Clin 2009; 49 (2): 121-34
170. Jonas JB. Intravitreal triamcinolone acetonide: a change ina paradigm. Ophthalmic Res 2006; 38 (4): 218-45
171. Blankenship GW. Evaluation of a single intravitreal injec-tion of dexamethasone phosphate in vitrectomy surgery for diabetic retinopathy complications. Graefes Arch Clin Exp Ophthalmol 1991; 229 (1): 62-5
172. Danis RP, Bingaman DP, Yang Y, et al. Inhibition ofpreretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103 (12): 2099-104
173. Penfold PL, Wen L, Madigan MC, et al. Modulation ofpermeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002; 43 (9): 3125-30
174. Matsuda S, Gomi F, Oshima Y, et al. Vascular endothelialgrowth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxida-tive stress. Invest Ophthalmol Vis Sci 2005; 46 (3): 1062-8
175. Brooks Jr HL, Caballero Jr S, Newell CK, et al. Vitreouslevels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004; 122 (12): 1801-7
176. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy.Lancet 2010; 376 (9735): 124-36
177. Silva PS, Sun JK, Aiello LP. Role of steroids in the man-agement of diabetic macular edema and proliferative diabetic retinopathy. Semin Ophthalmol 2009; 24 (2): 93-9
178. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitrealtriamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009; 116 (5): 902-11
179. Jonas JB. Intravitreal triamcinolone acetonide for diabeticretinopathy. Dev Ophthalmol 2007; 39: 96-110
180. Gillies MC, Sutter FK, Simpson JM, et al. Intravitrealtriamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113 (9): 1533-8
181. Gillies MC, Simpson JM, Gaston C, et al. Five-year resultsof a randomized trial with open-label extension of triam-cinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116 (11): 2182-7
182. Diabetic Retinopathy Clinical Research Network. A ran-domized trial comparing intravitreal triamcinolone acet-onide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115 (9): 1447-59
183. Beck RW, Edwards AR, Aiello LP, et al. Three-yearfollow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127 (3): 245-51
184. Bressler NM, Edwards AR, Beck RW, et al. Exploratoryanalysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares in-travitreal triamcinolone acetonide with focal/grid photo-coagulation. Arch Ophthalmol 2009; 127 (12): 1566-71
185. Ockrim ZK, Sivaprasad S, Falk S, et al. Intravitrealtriamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 2008; 92 (6): 795-9
186. Gillies MC, Simpson JM, Zhu M, et al. Intravitreal triam-cinolone [letter]. Ophthalmology 2009; 116 (3): 591
187. Larsson J, Kifley A, Zhu M, et al. Rapid reduction of hardexudates in eyes with diabetic retinopathy after in-travitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol 2009; 87 (3): 275-80
188. Bandello F, Polito A, Pognuz DR, et al. Triamcinolone asadjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy. Arch Ophthalmol 2006; 124 (5): 643-50
189. Lam DS, Chan CK, Mohamed S, et al. Intravitreal triam-cinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007; 114 (12): 2162-7
190. Maia Jr OO, Takahashi BS, Costa RA, et al. Combinedlaser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol 2009; 147 (2): 291-7
191. Lee HY, Lee SY, Park JS. Comparison of photocoagula-tion with combined intravitreal triamcinolone for diabetic macular edema. Korean J Ophthalmol 2009; 23 (3): 153-8
192. Mirshahi A, Shenazandi H, Lashay A, et al. Intravitrealtriamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 2010; 30 (2): 254-9
193. Shimura M, Nakazawa T, Yasuda K, et al. Pretreatment ofposterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol 2007; 91 (4): 449-54
194. Chung EJ, Freeman WR, Azen SP, et al. Comparison ofcombination posterior sub-tenon triamcinolone and modified grid laser treatment with intravitreal triamcino-lone treatment in patients with diffuse diabetic macular edema. Yonsei Med J 2008; 49 (6): 955-64
195. Unoki N, Nishijima K, Kita M, et al. Randomised con-trolled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy. Br J Ophthalmol 2009; 93 (6): 765-70
196. Gillies MC, McAllister IL, Zhu M, et al. Pretreatmentwith intravitreal triamcinolone prior to laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci 2010; 51: 2322-8
197. Kim Y, Kang S, Yi C-H. Three-year follow-up of in-travitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema. Invest Ophthalmol Vis Sci 2010; 51: E-Abstract 4260
198. Efficacy study of triamcinolone associated with nepafenacfor treatment of diabetic macular edema [Clinical Trials.gov identifier NCT00780780]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
199. US National Institutes of Health. ClinicalTrials.gov [on-line]. Available from URL: http//clinicaltrials.gov/ [Accessed 2010 May 5].
200. Mansoor S, Kuppermann BD, Kenney MC. Intraocularsustained-release delivery system for triamcinolone acet-onide. Pharm Res 2009; 26 (4): 770-84
201. A study of the safety and efficacy of a new treatmentfor diabetic macular edema [ClinicalTrials.gov identifier NCT00168389]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Aug 17].
202. A study of the safety and efficacy of a new treatment fordiabetic macular edema [ClinicalTrials.gov identifier NCT00168337]. US National Institutes of Health, Clin-icalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2010 Aug 17].
203. Kuppermann BD, Blumenkranz MS, Haller JA, et al.Randomized controlled study of an intravitreous dexa-methasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125 (3): 309-17
204. Haller JA, Kuppermann BD, Blumenkranz MS, et al.Randomized controlled trial of an intravitreous dexa-methasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128 (3): 289-96
205. Kuppermann BD, Chou C, Weinberg DV, et al. Intravitre-ous dexamethasone effects on different patterns of diabetic macular edema [letter]. Arch Ophthalmol 2010; 128 (5): 642-3
206. Pharmacokinetic and efficacy study of fluocinolone acet-onide inserts in patients with diabetic macular edema [ClinicalTrials.gov identifier NCT00490815]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
207. Fluocinolone acetonide implant compared to sham injec-tion in patients with diabetic macular edema [Clinical Trials.gov identifier NCT00344968]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
208. Campochiaro PA, Hafiz G, Shah SM, et al. Sustainedocular delivery of fluocinolone acetonide by an in-travitreal insert. Ophthalmology 2010; 117 (7): 1393-9.e3
209. Prospective, randomized, multi-center, comparator studyevaluating efficacy and safety of PF-04523655 versus laser in subjects with diabetic macular edema [ClinicalTrials. gov identifier NCT00701181]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17]
210. Campochiaro PA, Shah SM, Hafiz G, et al. Topical mec-amylamine for diabetic macular edema. Am J Ophthalmol 2010; 149 (5): 839-51
211. Leung DW, Cachianes G, Kuang WJ, et al. Vascular en-dothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246 (4935): 1306-9
212. Csaky KG, Baffi JZ, Byrnes GA, et al. Recruitment ofmarrow-derived endothelial cells to experimental cho-roidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 2004; 78 (6): 1107-16
213. Alon T, Hemo I, Itin A, et al. Vascular endothelial growthfactor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1 (10): 1024-8
214. 2 terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50 (6): 1774-8
215. Roberts WG, Palade GE. Increased microvascular perme-ability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995; 108 (Pt 6): 2369-79
216. Antonetti DA, Khin S, Lieth E, et al., and the Penn StateRetina Research Group. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 1998; 47 (12): 1953-9
217. Antonetti DA, Barber AJ, Hollinger LA, et al. Vascularendothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274 (33): 23463-7
218. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proin-flammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44 (5): 2155-62
219. Miyamoto K, Hiroshiba N, Tsujikawa A, et al. In vivodemonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 1998; 39 (11): 2190-4
220. Joussen AM, Poulaki V, Le ML, et al. A central role forinflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18 (12): 1450-2
221. Joussen AM, Poulaki V, Mitsiades N, et al. Suppression ofFas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J 2003; 17 (1): 76-8
222. Clauss M, Gerlach M, Gerlach H, et al. Vascular perme-ability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172 (6): 1535-45
223. Barleon B, Sozzani S, Zhou D, et al. Migration of humanmonocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87 (8): 3336-43
224. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediatedinflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198 (3): 483-9
225. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regula-tion of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113 (12): 1538-44
226. Miyamoto K, Khosrof S, Bursell SE, et al. Preventionof leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci \USA 1999; 96 (19): 10836-41
227. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endo-thelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331 (22): 1480-7
228. Adamis AP, Miller JW, Bernal MT, et al. Increased vas-cular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Oph-thalmol 1994; 118 (4): 445-50
229. Joussen AM, Smyth N, Niessen C. Pathophysiology ofdiabetic macular edema. Dev Ophthalmol 2007; 39: 1-12
230. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologicfeatures of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133 (3): 373-85
231. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitre-ous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103 (11): 1820-8
232. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targetedanti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5 (2): 123-32
233. Ferrara N, Damico L, Shams N, et al. Development ofranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26 (8): 859-70
234. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al.Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351 (27): 2805-16
235. Brown DM, Kaiser PK, Michels M, et al. Ranibizumabversus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432-44
236. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab forneovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1419-31
237. Lynch SS, Cheng CM. Bevacizumab for neovascular oculardiseases. Ann Pharmacother 2007; 41 (4): 614-25
238. DME and VEGF Trap-Eye: investigation of clinical impact[ClinicalTrials. gov identifier NCT00789477]. US National Institutes of Health ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
239. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: aVEGF blocker with potent antitumor effects. Proc Natl Acad Sci \USA 2002; 99 (17): 11393-8
240. Do DV, Nguyen QD, Shah SM, et al. An exploratory studyof the safety, tolerability and bioactivity of a single intra-vitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol 2009; 93 (2): 144-9
241. Safety and efficacy study of small interfering RNA molecule(Cand5) to treat diabetic macular edema [ClinicalTrials. gov identifier NCT00306904]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
242. Stahl A, Paschek L, Martin G, et al. Rapamycin reducesVEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 2008; 582 (20): 3097-102
243. Kim DD, Kleinman D, Kanetaka T, et al. Rapamycin in-hibits VEGF-induced microvascular hyperpermeability. Microcirculation 2010; 17(2): 128-36
244. Dose ranging study of an ocular sirolimus (rapamycin)formulation in patients with diabetic macular edema [ClinicalTrials.gov identifier NCT00656643]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
245. Cunningham Jr ET, Adamis AP, Altaweel M, et al. A phaseII randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112 (10): 1747-57
246. Adamis AP, Altaweel M, Bressler NM, et al. Changes inretinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113 (1): 23-8
247. Chun DW, Heier JS, Topping TM, et al. A pilot study ofmultiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113 (10): 1706-12
248. Goodart R, Faber DW, Mehr DS, et al. Lucentis in thetreatment of macular edema (LIME): a phase II study evaluating the safety and efficacy of ranibizumab versus focal laser treatment in patients with diabetic macular edema [abstract]. Invest Ophthalmol Vis Sci 2007; 48: E-Abstract 1431
249. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular en-dothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142 (6): 961-9
250. Wolf S, Massin P, Bandello F, et al. Safety and efficacy ofranibizumab treatment in patients with diabetic macular edema: 12-months results of the Resolve study [abstract]. Invest Ophthalmol Vis Sci 2009; 50: E-Abstract 4331
251. Arevalo JF, Sanchez JG, Lasave AF, The Pan-AmericanCollaborative Retina Study Group (PACORES). Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: the 2008 Juan Verdaguer-Planas Lecture. Curr Diabetes Rev. Epub 2010 Jul 1
252. Tonello M, Costa RA, Almeida FP, et al. Panretinal pho-tocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008; 86 (4): 385-9
253. Mirshahi A, Roohipoor R, Lashay A, et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008; 18 (2): 263-9
254. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitrealbevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008; 18 (6): 941-8
255. Nicholson BP, Schachat AP. A review of clinical trials ofanti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248 (7): 915-30
256. Ergun E, Macugen Diabetic Retinopathy Study Group. Pegaptanib therapy for diabetic macular edema (DME): two year follow-up. 16th Congress of the European Society of Ophthalmology; 2007 Jun 9-15; Vienna A multi-center trial to evaluate the safety and efficacy ofpegaptanib sodium (Macugen) injected into the eye every6 weeks for up to 2 years for macular swelling associated with diabetes, with an open-label Macugen year extension [ClinicalTrials.gov identifier NCT00605280]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17]
257. Gonzalez VH, Giuliari GP, Banda RM, et al. Intravitrealinjection of pegaptanib sodium for proliferative diabetic retinopathy. Br J Ophthalmol 2009; 93 (11): 1474-8
258. Morilla Gomez Y, Giuliari GP, Guel DA, et al. Pegaptanibsodium (Macugen) as an adjunct in proliferative diabetic retinopathy refractory to laser treatment [abstract]. Invest Ophthalmol Vis Sci 2008: E-Abstract 2761
259. Bevacizumab versus ranibizumab for diabetic retinopathy[ClinicalTrials. gov identifier NCT00545870]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17]
260. Nguyen QD, Shah SM, Heier JS, et al. Primary end point(six months) results of the Ranibizumab for Edema of the Macula in Diabetes (READ-2) study. Ophthalmology 2009; 116 (11): 2175-81.e1
261. Diabetic Retinopathy Clinical Research Network, ElmanMJ, Aiello LP, et al. Randomized trial evaluating ranibiz-umab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117 (6): 1064-77.e35
262. Laser-ranibizumab-triamcinolone for proliferative diabeticretinopathy [ClinicalTrials.gov identifier NCT00445003]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 17].
263. Goyal S, Lavalley M, Subramanian ML. Meta-analysisand review on the effect of bevacizumab in diabetic mac-ular edema. Graefes Arch Clin Exp Ophthalmol. Epub 2010 Jul 28
264. Cho WB, Oh SB, Moon JW, et al. Panretinal photo-coagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009; 29 (4): 516-22
265. Michaelides M, Kaines A, Hamilton RD, et al. A pro-spective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117 (6): 1078-86.e2
266. Soheilian M, Ramezani A, Obudi A, et al. Randomizedtrial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116 (6): 1142-50
267. Cho WB, Moon JW, Kim HC. Intravitreal triamcinoloneand bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthal-mol 2010; 94 (7): 858-63
268. Takamura Y, Kubo E, Akagi Y. Analysis of the effect ofintravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009; 116 (6): 1151-7
269. Simo R, Hernandez C. Intravitreous anti-VEGF for dia-betic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008; 51 (9): 1574-80
270. Sang DN, D'Amore PA. Is blockade of vascular en-dothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 2008; 51 (9): 1570-3
271. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: onceregarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004; 26 (9): 943-54
272. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelialgrowth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171 (1): 53-67
273. Saint-Geniez M, Maharaj AS, Walshe TE, et al. Endo-genous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS One 2008; 3 (11): e3554
274. Kamba T, Tam BY, HashizumeH, etal. VEGF-dependentplasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006; 290 (2): H560-76
275. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hy-pertrophic cartilage remodeling, ossification and angio-genesis during endochondral bone formation. Nat Med 1999; 5 (6): 623-8
276. Eremina V, Sood M, Haigh J, et al. Glomerular-specificalterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111 (5): 707-16
277. Gordon MS, Cunningham D. Managing patients treatedwith bevacizumab combination therapy. Oncology 2005; 69 Suppl. 3: 25-33
278. Scappaticci FA, Skillings JR, Holden SN, et al. Arterialthromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99 (16): 1232-9
279. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors ofocular neovascularization: promises and potential problems. JAMA 2005; 293 (12): 1509-13
280. Matsuyama K, Ogata N, Matsuoka M, et al. Plasma levelsof vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010; 94 (9): 1215-8
281. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarizedvascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner cho-riocapillaris: evidence for a trophic paracrine relation. Am J Pathol 1999; 155 (2): 421-8
282. Apte RS, Modi M, Masonson H, et al. Pegaptanib 1-yearsystemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007; 114 (9): 1702-12
283. Singerman LJ, Masonson H, Patel M, et al. Pegaptanibsodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92 (12): 1606-11
284. Marcus DM, VEGF Inhibition Study Ocular Neovas-cularization Clinical Trial Group. Four-year safety of pegaptanib sodium in neovascular age-related macular degeneration (AMD): results of the V.I.S.I.O.N. trial [abstract]. Invest Ophthalmol Vis Sci 2008; 49: E-Abstract 5069
285. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb studyto evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116 (9): 1731-9
286. Ueta T, Yanagi Y, Tamaki Y, et al. Cerebrovascular acci-dents in ranibizumab [letter]. Ophthalmology 2009; 116 (2): 362
287. Gillies MC, Wong TY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007; 356 (7): 748-9; author reply 749-50
288. Moradian S, Ahmadich H, Malihi M, et al. Intravitrealbevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2008; 246 (12): 1699-705
289. Gordon-Angelozzi M, Velez-Montoya R, Quiroz-MercadoH, et al. Bevacizumab local complications [letter]. Ophthalmology 2009; 116 (11): 2264.e1-3
290. Jonas JB, Schmidbauer M, Rensch F. Progression of trac-tional retinal detachment following intravitreal bev-acizumab. Acta Ophthalmol 2009; 87 (5): 571-2
291. Arevalo JF, Maia M, Flynn Jr HW, et al. Tractional retinaldetachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92 (2): 213-6
292. Krishnan R, Goverdhan S, Lochhead J. Intravitrealpegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye (Lond) 2009; 23 (5): 1238-9
293. Batman C, Ozdamar Y. The relation between bevacizumabinjection and the formation of subretinal fibrosis in diabetic patients with panretinal photocoagulation. Ophthalmic Surg Lasers Imaging 2010; 41 (2): 190-5
294. Bradley JR. TNF-mediated inflammatory disease. J Pathol2008; 214 (2): 149-60
295. Kim KA, Lee MS. Recent progress in research on beta-cellapoptosis by cytokines. Front Biosci 2009; 14: 657-64
296. Ortis F, Pirot P, Naamane N, et al. Induction of nuclearfactor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia 2008; 51 (7): 1213-25
297. Ruan H, Lodish HF. Insulin resistance in adipose tissue:direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 2003; 14 (5): 447-55
298. Demircan N, Safran BG, Soylu M, et al. Determination ofvitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 2006; 20 (12): 1366-9
299. Adamiec-Mroczek J, Oficjalska-Mynczak J, Misiuk-Hojo M. Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic ret-inopathy: analysis of vitreous samples. Cytokine 2010; 49 (3): 269-74
300. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cyto-kines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001; 15 (5): 257-9
301. Behl Y, Krothapalli P, Desta T, et al. Diabetes-enhancedtumor necrosis factor-alpha production promotes apop-tosis and the loss of retinal microvascular cells in type 1and type 2 models of diabetic retinopathy. Am J Pathol 2008; 172 (5): 1411-8
302. Shi X, Semkova I, Muther PS, et al. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp Eye Res 2006; 83 (6): 1325-34
303. Olson JL, Courtney RJ, Mandava N. Intravitreal in-fliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007; 125 (9): 1221-4
304. Hangai M, He S, Hoffmann S, et al. Sequential inductionof angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol 2006; 171 (1-2): 45-56
305. Sfikakis PP, Markomichelakis N, Theodossiadis GP, et al.Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005; 28 (2): 445-7
306. Markomichelakis NN, Theodossiadis PG, Sfikakis PP.Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005; 139 (3): 537-40
307. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. In-travitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009; 147 (5): 825-30
308. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. In-fliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32 weeks study. Diabetes Care 2010; 33 (7): 1523-8
309. Suhler EB, Smith JR, Wertheim MS, et al. A prospectivetrial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123 (7): 903-12
310. Giganti M, Beer PM, Lemanski N, et al. Adverse eventsafter intravitreal infliximab (Remicade). Retina 2010; 30 (1): 71-80
311. Danis RP, Sheetz MJ. Ruboxistaurin: PKC-beta inhibitionfor complications of diabetes. Expert Opin Pharmacother 2009; 10 (17): 2913-25
312. Aiello LP, Bursell SE, Clermont A, et al. Vascular en-dothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46 (9): 1473-80
313. Harhaj NS, Felinski EA, Wolpert EB, et al. VEGF acti-vation of protein kinase C stimulates occludin phosphor-ylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47 (11): 5106-15
314. PKC-DMES Study Group. The effect of ruboxistaurin onvisual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinop-athy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54 (7): 2188-97
315. Aiello LP, Davis MD, Girach A, et al. Effect of rubox-istaurin on visual loss in patients with diabetic retinop-athy. Ophthalmology 2006; 113 (12): 2221-30
316. PKC-DMES Study Group. Effect of ruboxistaurin inpatients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007; 125 (3): 318-24
317. Effect of ruboxistaurin on clinically significant macularedema [ClinicalTrials.gov identifier NCT00133952]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: